EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 2
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
How EHR-based Recruitment and Retention supports Patients Centricity
Volume 11 Issue 2

How EHR-based Recruitment and Retention supports Patients Centricity

Patient-centricity has arisen from the idea that the development of new treatments can be better done by redesigning its processes around the needs of patients, and ...
25 April 2019 Volume 11 Issue 2
Continue Reading →
news

Redesigned CAR-T eliminates dangerous cytokine release syndrome in lymphoma trial

CAR-T treatments for blood cancer are often given on an inpatient basis so patients can be monitored for dangerous side effects. University of Southern California r...
23 April 2019 news | North America | Regional News
Continue Reading →
Europe

Roche throws in the towel on Tecentriq bladder, myeloma trials

Roche's Tecentriq nabbed key approvals in breast cancer and small-cell lung cancer last month.  Roche’s Tecentriq has scored some important victories lately, inc...
23 April 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Pfizer posts positive data for 20-strain pneumococcal vaccine

A Pfizer vaccine candidate meant to protect against 20 different strains of pneumococcal disease was well-tolerated, safe and elicited an immune response in a Phase ...
23 April 2019 Europe | news | North America | Regional News
Continue Reading →
Europe

Clovis shares slide on Rubraca trial discontinuation

Clovis Oncology's shares have fallen by roughly 15% since the biotech disclosed the halting of a Phase 2 study of Rubraca in recurrent, metastatic bladder cancer....
23 April 2019 Europe | news | North America | Regional News
Continue Reading →
news

United Therapeutics scraps drug after late-stage miss

An experimental drug for a rare lung condition has failed in a registrational trial, prompting its manufacturer, United Therapeutics, to halt further development....
23 April 2019 news | North America | Regional News
Continue Reading →
news

Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of th...
23 April 2019 news | North America | Regional News
Continue Reading →
news

High-dose vitamin D shows benefit in patients with advanced colorectal cancer

Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by dela...
18 April 2019 news | North America | Regional News
Continue Reading →
news

Alnylam looks to next RNAi approval, but safety questions linger

Alnylam on Friday released full results from a pivotal Phase 3 study for givosiran, setting the stage for the company to finish a U.S. regulatory application in t...
18 April 2019 news | North America | Regional News
Continue Reading →
news

Clovis throws in the towel on solo Rubraca study in bladder cancer

Clovis Oncology's PARP inhibitor Rubraca fell short in its monotherapy bladder cancer test, but it's on track for a first-in-class approval in prostate cancer. (Clo...
18 April 2019 news | North America | Regional News
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2025, All Rights Reserved – Powered by Teksyte